- Home
- BNZI vs INAB Comparison
BNZI vs INAB Comparison
Compare BNZI & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNZI
- INAB
- Stock Information
- Founded
- BNZI 2016
- INAB 2016
- Country
- BNZI United States
- INAB United States
- Employees
- BNZI N/A
- INAB N/A
- Industry
- BNZI
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- BNZI
- INAB Health Care
- Exchange
- BNZI Nasdaq
- INAB Nasdaq
- Market Cap
- BNZI 11.5M
- INAB 10.8M
- IPO Year
- BNZI N/A
- INAB 2021
- Fundamental
- Price
- BNZI $3.21
- INAB $2.40
- Analyst Decision
- BNZI Strong Buy
- INAB Strong Buy
- Analyst Count
- BNZI 1
- INAB 2
- Target Price
- BNZI $30.00
- INAB $108.00
- AVG Volume (30 Days)
- BNZI 420.1K
- INAB 79.2K
- Earning Date
- BNZI 11-13-2025
- INAB 11-11-2025
- Dividend Yield
- BNZI N/A
- INAB N/A
- EPS Growth
- BNZI N/A
- INAB N/A
- EPS
- BNZI N/A
- INAB N/A
- Revenue
- BNZI $9,021,543.00
- INAB N/A
- Revenue This Year
- BNZI $292.46
- INAB N/A
- Revenue Next Year
- BNZI $82.82
- INAB N/A
- P/E Ratio
- BNZI N/A
- INAB N/A
- Revenue Growth
- BNZI 107.94
- INAB N/A
- 52 Week Low
- BNZI $2.08
- INAB $1.91
- 52 Week High
- BNZI $68.90
- INAB $16.70
- Technical
- Relative Strength Index (RSI)
- BNZI 58.17
- INAB 62.04
- Support Level
- BNZI $2.56
- INAB $2.14
- Resistance Level
- BNZI $3.00
- INAB $2.49
- Average True Range (ATR)
- BNZI 0.26
- INAB 0.15
- MACD
- BNZI 0.08
- INAB 0.04
- Stochastic Oscillator
- BNZI 80.17
- INAB 83.00
About BNZI Banzai International Inc.
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.